These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 23191966)

  • 1. [Prevention of severe toxicity from capecitabine, 5-fluorouracil and tegafur by screening for DPD-deficiency].
    Deenen MJ; Cats A; Mandigers CM; Soesan M; Terpstra WE; Beijnen JH; Schellens JH
    Ned Tijdschr Geneeskd; 2012; 156(48):A4934. PubMed ID: 23191966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Detection of dihydropyrimidine dehydrogenase deficiency before treatment by fluoropyrimidines].
    Gamelin E; Boisdron-Celle M; Morel A
    Therapie; 2007; 62(2):99-103. PubMed ID: 17582309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Review of methods for determination of dihydropyrimidine dehydrogenase and possible application in screening previous chemotheraphy with 5-fluorouracil].
    Ostapowicz A; Dołegowska B
    Przegl Lek; 2012; 69(9):694-7. PubMed ID: 23401991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Capecitabine-based treatment of a patient with a novel DPYD genotype and complete dihydropyrimidine dehydrogenase deficiency.
    Henricks LM; Siemerink EJM; Rosing H; Meijer J; Goorden SMI; Polstra AM; Zoetekouw L; Cats A; Schellens JHM; van Kuilenburg ABP
    Int J Cancer; 2018 Jan; 142(2):424-430. PubMed ID: 28929491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The contribution of deleterious DPYD gene sequence variants to fluoropyrimidine toxicity in British cancer patients.
    Loganayagam A; Arenas-Hernandez M; Fairbanks L; Ross P; Sanderson JD; Marinaki AM
    Cancer Chemother Pharmacol; 2010 Jan; 65(2):403-6. PubMed ID: 19795123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.
    Henricks LM; Lunenburg CATC; de Man FM; Meulendijks D; Frederix GWJ; Kienhuis E; Creemers GJ; Baars A; Dezentjé VO; Imholz ALT; Jeurissen FJF; Portielje JEA; Jansen RLH; Hamberg P; Ten Tije AJ; Droogendijk HJ; Koopman M; Nieboer P; van de Poel MHW; Mandigers CMPW; Rosing H; Beijnen JH; Werkhoven EV; van Kuilenburg ABP; van Schaik RHN; Mathijssen RHJ; Swen JJ; Gelderblom H; Cats A; Guchelaar HJ; Schellens JHM
    Lancet Oncol; 2018 Nov; 19(11):1459-1467. PubMed ID: 30348537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Upfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis.
    Deenen MJ; Meulendijks D; Cats A; Sechterberger MK; Severens JL; Boot H; Smits PH; Rosing H; Mandigers CM; Soesan M; Beijnen JH; Schellens JH
    J Clin Oncol; 2016 Jan; 34(3):227-34. PubMed ID: 26573078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Profiling dihydropyrimidine dehydrogenase deficiency in patients with cancer undergoing 5-fluorouracil/capecitabine therapy.
    Mercier C; Ciccolini J
    Clin Colorectal Cancer; 2006 Nov; 6(4):288-96. PubMed ID: 17241513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patients homozygous for DPYD c.1129-5923C>G/haplotype B3 have partial DPD deficiency and require a dose reduction when treated with fluoropyrimidines.
    Meulendijks D; Henricks LM; van Kuilenburg AB; Jacobs BA; Aliev A; Rozeman L; Meijer J; Beijnen JH; de Graaf H; Cats A; Schellens JH
    Cancer Chemother Pharmacol; 2016 Oct; 78(4):875-80. PubMed ID: 27544765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: Ready for prime time.
    Lunenburg CATC; Henricks LM; Guchelaar HJ; Swen JJ; Deenen MJ; Schellens JHM; Gelderblom H
    Eur J Cancer; 2016 Feb; 54():40-48. PubMed ID: 26716401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing.
    Caudle KE; Thorn CF; Klein TE; Swen JJ; McLeod HL; Diasio RB; Schwab M
    Clin Pharmacol Ther; 2013 Dec; 94(6):640-5. PubMed ID: 23988873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DPYD*2A mutation: the most common mutation associated with DPD deficiency.
    Saif MW; Ezzeldin H; Vance K; Sellers S; Diasio RB
    Cancer Chemother Pharmacol; 2007 Sep; 60(4):503-7. PubMed ID: 17165084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data.
    Meulendijks D; Henricks LM; Sonke GS; Deenen MJ; Froehlich TK; Amstutz U; Largiadèr CR; Jennings BA; Marinaki AM; Sanderson JD; Kleibl Z; Kleiblova P; Schwab M; Zanger UM; Palles C; Tomlinson I; Gross E; van Kuilenburg AB; Punt CJ; Koopman M; Beijnen JH; Cats A; Schellens JH
    Lancet Oncol; 2015 Dec; 16(16):1639-50. PubMed ID: 26603945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is capecitabine safe in patients with gastrointestinal cancer and dihydropyrimidine dehydrogenase deficiency?
    Saif MW; Diasio R
    Clin Colorectal Cancer; 2006 Jan; 5(5):359-62. PubMed ID: 16512996
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2021; 21(14):1-186. PubMed ID: 34484488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Severe toxicity following capecitabine administration because of dihydropyrimidine deshydrogenase (DPD) deficiency].
    Coursier S; Martelet S; Guillermet A; Emptoz J; Villier C; Bontemps H
    Gastroenterol Clin Biol; 2010 Mar; 34(3):218-23. PubMed ID: 20219304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Severe toxicity after treatment with capecitabine and fluorouracil due to partial dihydropyrimidine dehydrogenase deficiency].
    Hooiveld EA; van Kuilenburg AB; Haanen JB; Westermann AM
    Ned Tijdschr Geneeskd; 2004 Mar; 148(13):626-8. PubMed ID: 15083629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of DPYD and fluoropyrimidines.
    Lunenburg CATC; van der Wouden CH; Nijenhuis M; Crommentuijn-van Rhenen MH; de Boer-Veger NJ; Buunk AM; Houwink EJF; Mulder H; Rongen GA; van Schaik RHN; van der Weide J; Wilffert B; Deneer VHM; Swen JJ; Guchelaar HJ
    Eur J Hum Genet; 2020 Apr; 28(4):508-517. PubMed ID: 31745289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severe fluoropyrimidine toxicity due to novel and rare DPYD missense mutations, deletion and genomic amplification affecting DPD activity and mRNA splicing.
    van Kuilenburg AB; Meijer J; Maurer D; Dobritzsch D; Meinsma R; Los M; Knegt LC; Zoetekouw L; Jansen RL; Dezentjé V; van Huis-Tanja LH; van Kampen RJ; Hertz JM; Hennekam RC
    Biochim Biophys Acta Mol Basis Dis; 2017 Mar; 1863(3):721-730. PubMed ID: 28024938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Should DPD analysis be required prior to prescribing fluoropyrimidines?
    Yen JL; McLeod HL
    Eur J Cancer; 2007 Apr; 43(6):1011-6. PubMed ID: 17350823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.